Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Pancreatic Endocrine Tumor Drug market report explains the definition, types, applications, major countries, and major players of the Pancreatic Endocrine Tumor Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Jiangsu Hengrui Medicine Co Ltd
MediaPharma srl
OXiGENE Inc
Novartis AG
Ipsen SA
By Type:
Buparlisib Hydrochloride
Dovitinib Lactate
Fosbretabulin Tromethamine
Lanreotide Acetate
MPHE-001B
Others
By End-User:
Clinic
Research Center
Hospital
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Pancreatic Endocrine Tumor Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Pancreatic Endocrine Tumor Drug Outlook to 2028- Original Forecasts
-
2.2 Pancreatic Endocrine Tumor Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Pancreatic Endocrine Tumor Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Pancreatic Endocrine Tumor Drug Market- Recent Developments
-
6.1 Pancreatic Endocrine Tumor Drug Market News and Developments
-
6.2 Pancreatic Endocrine Tumor Drug Market Deals Landscape
7 Pancreatic Endocrine Tumor Drug Raw Materials and Cost Structure Analysis
-
7.1 Pancreatic Endocrine Tumor Drug Key Raw Materials
-
7.2 Pancreatic Endocrine Tumor Drug Price Trend of Key Raw Materials
-
7.3 Pancreatic Endocrine Tumor Drug Key Suppliers of Raw Materials
-
7.4 Pancreatic Endocrine Tumor Drug Market Concentration Rate of Raw Materials
-
7.5 Pancreatic Endocrine Tumor Drug Cost Structure Analysis
-
7.5.1 Pancreatic Endocrine Tumor Drug Raw Materials Analysis
-
7.5.2 Pancreatic Endocrine Tumor Drug Labor Cost Analysis
-
7.5.3 Pancreatic Endocrine Tumor Drug Manufacturing Expenses Analysis
8 Global Pancreatic Endocrine Tumor Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Pancreatic Endocrine Tumor Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Pancreatic Endocrine Tumor Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Pancreatic Endocrine Tumor Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Pancreatic Endocrine Tumor Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Buparlisib Hydrochloride Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Dovitinib Lactate Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Fosbretabulin Tromethamine Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Lanreotide Acetate Consumption and Growth Rate (2017-2022)
-
9.1.5 Global MPHE-001B Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Pancreatic Endocrine Tumor Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Research Center Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Hospital Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Pancreatic Endocrine Tumor Drug Market Analysis and Outlook till 2022
-
10.1 Global Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.2.2 Canada Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.2.3 Mexico Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.2 UK Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.3 Spain Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.4 Belgium Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.5 France Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.6 Italy Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.7 Denmark Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.8 Finland Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.9 Norway Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.10 Sweden Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.11 Poland Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.12 Russia Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.3.13 Turkey Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.2 Japan Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.3 India Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.4 South Korea Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.5 Pakistan Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.7 Indonesia Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.8 Thailand Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.9 Singapore Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.10 Malaysia Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.11 Philippines Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.4.12 Vietnam Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5.2 Colombia Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5.3 Chile Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5.4 Argentina Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5.5 Venezuela Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5.6 Peru Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.5.8 Ecuador Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.6.2 Kuwait Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.6.3 Oman Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.6.4 Qatar Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.7.2 South Africa Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.7.3 Egypt Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.7.4 Algeria Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
-
10.8.2 New Zealand Pancreatic Endocrine Tumor Drug Consumption (2017-2022)
11 Global Pancreatic Endocrine Tumor Drug Competitive Analysis
-
11.1 Jiangsu Hengrui Medicine Co Ltd
-
11.1.1 Jiangsu Hengrui Medicine Co Ltd Company Details
-
11.1.2 Jiangsu Hengrui Medicine Co Ltd Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Jiangsu Hengrui Medicine Co Ltd Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
11.1.4 Jiangsu Hengrui Medicine Co Ltd Pancreatic Endocrine Tumor Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 MediaPharma srl
-
11.2.1 MediaPharma srl Company Details
-
11.2.2 MediaPharma srl Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 MediaPharma srl Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
11.2.4 MediaPharma srl Pancreatic Endocrine Tumor Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 OXiGENE Inc
-
11.3.1 OXiGENE Inc Company Details
-
11.3.2 OXiGENE Inc Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 OXiGENE Inc Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
11.3.4 OXiGENE Inc Pancreatic Endocrine Tumor Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Novartis AG
-
11.4.1 Novartis AG Company Details
-
11.4.2 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
11.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Ipsen SA
-
11.5.1 Ipsen SA Company Details
-
11.5.2 Ipsen SA Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Ipsen SA Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
11.5.4 Ipsen SA Pancreatic Endocrine Tumor Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
12 Global Pancreatic Endocrine Tumor Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Buparlisib Hydrochloride Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Dovitinib Lactate Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Fosbretabulin Tromethamine Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Lanreotide Acetate Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global MPHE-001B Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Research Center Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Pancreatic Endocrine Tumor Drug Market Analysis and Outlook to 2028
-
13.1 Global Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.5 France Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.3 India Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Pancreatic Endocrine Tumor Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Pancreatic Endocrine Tumor Drug
-
Figure of Pancreatic Endocrine Tumor Drug Picture
-
Table Global Pancreatic Endocrine Tumor Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Pancreatic Endocrine Tumor Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Buparlisib Hydrochloride Consumption and Growth Rate (2017-2022)
-
Figure Global Dovitinib Lactate Consumption and Growth Rate (2017-2022)
-
Figure Global Fosbretabulin Tromethamine Consumption and Growth Rate (2017-2022)
-
Figure Global Lanreotide Acetate Consumption and Growth Rate (2017-2022)
-
Figure Global MPHE-001B Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Research Center Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Table North America Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Figure United States Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Figure Germany Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure France Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Figure China Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure India Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Table South America Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Figure Brazil Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Figure Bahrain Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Figure Nigeria Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Pancreatic Endocrine Tumor Drug Consumption by Country (2017-2022)
-
Figure Australia Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Pancreatic Endocrine Tumor Drug Consumption and Growth Rate (2017-2022)
-
Table Jiangsu Hengrui Medicine Co Ltd Company Details
-
Table Jiangsu Hengrui Medicine Co Ltd Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Jiangsu Hengrui Medicine Co Ltd Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
Table Jiangsu Hengrui Medicine Co Ltd Pancreatic Endocrine Tumor Drug Product Portfolio
-
Table MediaPharma srl Company Details
-
Table MediaPharma srl Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table MediaPharma srl Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
Table MediaPharma srl Pancreatic Endocrine Tumor Drug Product Portfolio
-
Table OXiGENE Inc Company Details
-
Table OXiGENE Inc Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table OXiGENE Inc Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
Table OXiGENE Inc Pancreatic Endocrine Tumor Drug Product Portfolio
-
Table Novartis AG Company Details
-
Table Novartis AG Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
Table Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio
-
Table Ipsen SA Company Details
-
Table Ipsen SA Pancreatic Endocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ipsen SA Pancreatic Endocrine Tumor Drug Main Business and Markets Served
-
Table Ipsen SA Pancreatic Endocrine Tumor Drug Product Portfolio
-
Figure Global Buparlisib Hydrochloride Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dovitinib Lactate Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Fosbretabulin Tromethamine Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lanreotide Acetate Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global MPHE-001B Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Research Center Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Table North America Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Figure China Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Pancreatic Endocrine Tumor Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Pancreatic Endocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)
-
